SCHEMBL907660

SCHEMBL907660

COC(=O)Cc1cccc(N)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.59
ALDH1A1 P00352 3/20 0.58
GAA P10253 1/20 0.58
GFER P55789 1/20 0.58
HSP90AB1 P08238 1/20 0.50
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
HPGD P15428 2/20 0.47
MAPT P10636 1/20 0.47
TSHR P16473 1/20 0.47
GLS O94925 2/20 0.46
TLR7 Q9NYK1 1/20 0.44
CTSG P08311 1/20 0.44
CMA1 P23946 1/20 0.44
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44
LOXL2 Q9Y4K0 1/20 0.44
CYP19A1 P11511 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PDK2 Q15119 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31478027 1.00 SLC7A5 (0.59) SLC7A5ALDH1A1GAAGFERHSP90AB1
Hydrochloric Acid SCHEMBL6984256 0.98 SLC7A5 (0.57) SLC7A5ALDH1A1GAAGFERHSP90AB1
Hydrochloric Acid SCHEMBL3949455 0.98 SLC7A5 (0.57) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL7880302 0.88 SLC7A5 (0.51) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL7882515 0.88 LOXL2 (0.51) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL12400239 0.87 SLC7A5 (0.68) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL7879148 0.86 SLC7A5 (0.50) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL28277222 0.85 MAOB (0.47) SLC7A5ALDH1A1GAAGFERGLS
SCHEMBL20515032 0.84 SMN1; SMN2 (0.49) SLC7A5ALDH1A1GAAGFERGLS
SCHEMBL1000850 0.84 MAOB (0.46) SLC7A5ALDH1A1GAAGFERGLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743082-A1 CARBAZOLE COMPOUNDS AND THEIR USE IN THERAPY, IN THE TREATMENT OF A RESPIRATORY INFECTION UCL Business Ltd (GB) 2026-05-20 EP disclosed
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-20250302815-A1 PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS CALICO LIFE SCIENCES LLC 2025-10-02 US disclosed
WO-2025108986-A1 2-AMINO-N-(OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2025-05-30 WO disclosed
US-12286435-B2 Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof BIONNA (BEIJING) MEDICAL TECHNOLOGY CO., LTD. (CN) 2025-04-29 US disclosed
US-12264169-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners (US) 2025-04-01 US disclosed
CN-116284033-B Tubulin/AKT 1 double-targeting podophyllotoxin derivative and application thereof 常州大学 2025-02-25 CN disclosed
CN-115466229-B Para-amidobenzenesulfonyl compound and application thereof 上海中医药大学 2025-01-24 CN disclosed
WO-2025012634-A1 CARBAZOLE COMPOUNDS AND THEIR USE IN THERAPY, IN THE TREATMENT OF A RESPIRATORY INFECTION UCL BUSINESS LTD (GB) 2025-01-16 WO disclosed
US-12195472-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2025-01-14 US disclosed
EP-0535034-A1 PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1993-04-07 EP disclosed
EP-0523845-A2 New benzodiazepine analogs MERCK & CO. INC. (US) 1993-01-20 EP disclosed
EP-0490590-A1 New benzodiazepine analogs MERCK & CO. INC. (US) 1992-06-17 EP disclosed
CN-1058208-A PHARMACEUTICAL COMPOUNDS WELLCOME FOUND (GB) 1992-01-29 CN disclosed
WO-1991019700-A1 PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1991-12-26 WO disclosed
EP-0434369-A1 New benzodiazepine analogs MERCK & CO. INC. (US) 1991-06-26 EP disclosed
EP-0434360-A1 New benziodiazepine analogs MERCK & CO. INC. (US) 1991-06-26 EP disclosed
US-4288364-A REACTING A 3-/2-HYDROXYIMINOACETYLAMINO/-2-OXOAZETIDINE WITH AN ORGANIC CARBONATE OR ACYL HALIDE CIBA-GEIGY CORPORATION (US) 1981-09-08 US disclosed
EP-0005507-A1 Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby CIBA-GEIGY AG (CH) 1979-11-28 EP disclosed
US-4067726-A 3-Ureido phenylacetamide herbicides BAYER AKTIENGESELLSCHAFT (DT) 1978-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302815-A1 PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS PTPN1, PTPN2, PTPN18 SLC7A5 3421/4885ALDH1A1 3874/4885GAA 414/4885
US-12264169-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C SLC7A5 3548/4885ALDH1A1 1152/4885GAA 497/4885
US-12286435-B2 Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof BRD4, BRD7, BICRA SLC7A5 3535/4885ALDH1A1 2921/4885GAA 3511/4885
US-12195472-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL3 SLC7A5 3195/4885ALDH1A1 1900/4885GAA 4009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.